Osimertinib approved for treating EGFR mutation positive NSCLC
Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults.
Read more on the National Institute for Care and Health Excellence website